Meta-Analysis of the Effects of Three-Dimensional Visualized Medical Techniques Hepatectomy for Liver Cancer with and without the Treatment of Sorafenib

Table 1

Basic characteristics and the bias risk evaluation of the included studies.

Author, year	Disease	Samples (3D/2D)	Age (3D/2D)	Outcomes	NOS
Fang, 2013	Hepatolithiasis	42/56	NA	2), 4), 5)	9
Fang, 2015a	Primary hepatic carcinoma	53/55	53 ± 11/49 ± 11	1), 2), 3), 5), 6)	9
Fang, 2015b	Primary hepatocellular carcinoma	56/64	46.5 ± 13.3/47.5 ± 13.8	1), 2), 3)	8
He, 2015	Echinococcosis of liver	47/59	NA	1), 2), 3)	9
Li, 2017	Primary hepatic carcinoma	24/26	NA	1), 2), 3)	6
Li, 2018	Hepatocellular carcinoma + cholangiocarcinoma + cholangiolithiasis + hepatic parasitosis + cholangiocarcinoma + hemangioma	172/220	42.4 ± 11.4	1), 2), 3), 4), 5), 6)	7
Nakayama, 2017	Hepatocellular carcinoma + intrahepatic cholangiocarcinoma + metastatic liver tumor	120/120	65 (22∼80)/67 (17∼81)	1), 2), 4)	7
Okuda, 2015	Primary cholangiocarcinoma	69/49	66 ± 9/64 ± 11	1), 2)	7
Song, 2020	Primary hepatic carcinoma	59/59	52.31 ± 4.33/51.68 ± 4.29	1), 2), 4), 5), 6)	8
Velayutham, 2016	Colorectal metastasis + hepatocellular carcinoma	40/20	NA	1), 2), 3), 4), 6)	6
Wang, 2021	Liver tumor	34/36	54.18 ± 14.42/59.17 ± 9.24	1), 6)	8
Wei, 2016	Hepatocellular carcinoma	43/31	48 ± 10.0/50.5 ± 10.6	1), 2), 3), 6)	8
Zhang, 2019	Primary hepatic carcinoma	30/34	55.7 ± 11.2/52.5 ± 12.1	1), 2), 6)	8

3D: three-dimensional; 2D: two-dimensional; (1) postoperative complications; (2) operating time; (3) intraoperative blood loss; (4) the incidence of liver failure; (5) the postoperative 1-year recurrence rates; (6) the postoperative 1-year survival rates.